Clinical Trials Browser

Phase 2 × NETWORK × telisotuzumab vedotin × Clear all

NCT03574753 2021-10-18

Lung-MAP S1400K: c-MET Positive

Phase 2 Completed

28 enrolled 18 charts

Recurrent Squamous Cell Lung Carcinoma